- Previous Close
1.380 - Open
1.330 - Bid 1.320 x --
- Ask 1.320 x --
- Day's Range
1.240 - 1.330 - 52 Week Range
1.030 - 2.280 - Volume
1,461,500 - Avg. Volume
1,877,465 - Market Cap (intraday)
1.305B - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.300 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.
www.huamedicine.com172
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 2552.HK
View MorePerformance Overview: 2552.HK
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2552.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2552.HK
View MoreValuation Measures
Market Cap
1.35B
Enterprise Value
221.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.70
Price/Book (mrq)
10.50
Enterprise Value/Revenue
1.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-241.76%
Return on Assets (ttm)
-17.81%
Return on Equity (ttm)
-300.57%
Revenue (ttm)
108.94M
Net Income Avi to Common (ttm)
-263.38M
Diluted EPS (ttm)
-0.300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.34B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-196.16M